97
Trials as lead sponsor
Most active programmes
The drugs appearing most often across United Therapeutics's recently active trials. Comparator arms are excluded.
- Inhaled Treprostinil7 trials
- treprostinil diethanolamine6 trials
- Oral Treprostinil5 trials
- treprostinil sodium5 trials
- Treprostinil Ultrasonic Nebulizer4 trials
- Ralinepag4 trials
Upcoming readouts
Next primary completion dates among United Therapeutics's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
Top therapeutic areas
Conditions studied most often across United Therapeutics's recently active trials.
- Pulmonary Arterial Hypertension46 trials
- Pulmonary Hypertension23 trials
- Interstitial Lung Disease8 trials
- Hypertension, Pulmonary6 trials
- PAH4 trials
- Idiopathic Pulmonary Fibrosis4 trials
United Therapeutics trials
The 50 most significant of United Therapeutics's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionNCT03683186Ralinepag | Phase 3 | Locked · track to reveal | OngoingEnrolling by invitation | 1,000 est. | Dec 2026 |
| ADAPTADAPT - A Patient Registry of the Real-world Use of Orenitram®NCT03045029Oral treprostinil | — | Not yet scored | OngoingActive, not recruiting | 300 est. | Mar 2027 |
| Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)NCT05943535Inhaled Treprostinil | Phase 3 | Locked · track to reveal | OngoingRecruiting | 698 est. | Nov 2027 |
| EXPANDStudy to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRDNCT0687856010 GE Xenokidney | Phase 1 | Locked · track to reveal | OngoingRecruiting | 50 est. | Oct 2028 |
| EXTENDStudy to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRDNCT07224763GGTA1 KO Thymokidney | Phase 1 | Locked · track to reveal | OngoingRecruiting | 50 est. | Mar 2029 |
| DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT06388421Prospective study assessments | — | Not yet scored | OngoingRecruiting | 900 est. | 1 Sept 2030 |
| TETON-OLEExtension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseaseNCT04905693Inhaled Treprostinil | Phase 3 | Locked · track to reveal | OngoingEnrolling by invitation | 1,850 est. | Jun 2026 |
| ARTISANA Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial HypertensionNCT05203510Parenteral Treprostinil | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 52 est. | 30 Apr 2026 |
| PHINDERPulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier DetectionNCT05776225Right heart catheterization (RHC) | — | Not yet scored | Completed | 314 est. | 13 Mar 2026 |
| TETON-1Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisNCT04708782Inhaled Treprostinil | Phase 3 | Locked · track to reveal | Completed | 598 est. | 2 Feb 2026 |
| miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 TrialNCT06285253miroliverELAP treatment | Phase 1 | Locked · track to reveal | Completed | 10 est. | 22 Jan 2026 |
| A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH PatientsNCT03626688Ralinepag | Phase 3 | Locked · track to reveal | Completed | 687 est. | 31 Dec 2025 |
| TETON-2Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisNCT05255991Inhaled Treprostinil | Phase 3 | Locked · track to reveal | Completed | 597 est. | 30 Jun 2025 |
| EVOLVEEvaluate Real-World Use of Next Generation Infusion Pumps to Administer RemodulinNCT05060315Remunity Pump for Remodulin | — | Not yet scored | StoppedTerminated | 9 est. | 31 Dec 2024 |
| BREEZEOpen-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using TyvasoNCT03950739Treprostinil Inhalation Powder | Phase 1 | Locked · track to reveal | Completed | 51 est. | 22 Aug 2023 |
| CAPACITYStudy of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH SubjectsNCT04084678Ralinepag | Phase 3 | Locked · track to reveal | StoppedTerminated | 10 est. | 12 Apr 2023 |
| PERFECT OLEInhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)NCT03794583Inhaled treprostinil solution | Phase 3 | Locked · track to reveal | StoppedTerminated | 41 est. | 29 Nov 2022 |
| PERFECTA Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)NCT03496623Inhaled treprostinil solution | Phase 3 | Locked · track to reveal | StoppedTerminated | 188 est. | 13 Oct 2022 |
| Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the NewbornNCT02261883IV Remodulin | Phase 2 | Locked · track to reveal | StoppedTerminated | 42 est. | 27 Sept 2022 |
| EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial HypertensionNCT03497689Intravenous/Subcutaneous Treprostinil; Oral Treprostinil | Phase 4 | Locked · track to reveal | Completed | 36 est. | 11 May 2022 |
| Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial HypertensionNCT02999906Oral Treprostinil | Phase 3 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Dec 2021 |
| Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)NCT03055234Oral Treprostinil | Phase 3 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Dec 2021 |
| An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionNCT01560637UT-15C (treprostinil diolamine) | Phase 3 | Locked · track to reveal | Completed | 471 est. | 12 Aug 2021 |
| An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFENCT02633293Inhaled Treprostinil | Phase 2 | Locked · track to reveal | StoppedTerminated | 243 est. | 1 Aug 2021 |
| An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial HypertensionNCT02882126Subcutaneous Treprostinil | Phase 4 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Jun 2021 |
| A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPDNCT03857841UNEX-42 | Phase 1 | Locked · track to reveal | StoppedTerminated | 3 est. | 20 May 2021 |
| Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial HypertensionNCT02279745Ralinepag | Phase 2 | Locked · track to reveal | Completed | 45 est. | 29 Mar 2021 |
| Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEFNCT03043651Oral treprostinil | Phase 3 | Locked · track to reveal | StoppedTerminated | 48 est. | 2 Mar 2020 |
| FREEDOM-EXTAn Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial HypertensionNCT01027949Oral Treprostinil | Phase 3 | Locked · track to reveal | Completed | 894 est. | 12 Feb 2020 |
| Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung CancerNCT03098030Dinutuximab | Phase 2 | Locked · track to reveal | Completed | 483 est. | 27 Jan 2020 |
| Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFENCT02630316Inhaled Treprostinil | Phase 2 | Locked · track to reveal | Completed | 326 est. | 26 Dec 2019 |
| Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection FractionNCT03037580Oral treprostinil | Phase 3 | Locked · track to reveal | StoppedTerminated | 84 est. | 3 Dec 2019 |
| PRNPatient Global Impression Questions for Activity-Induced Symptoms in Participants With PAHNCT03888365Treprostinil | — | Not yet scored | Completed | 43 est. | 19 Sept 2019 |
| BEAT OLEA Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial HypertensionNCT03657095Esuberaprost | Phase 3 | Locked · track to reveal | StoppedTerminated | 112 est. | 20 Jul 2019 |
| Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPDNCT03012646Inhaled Treprostinil | Phase 2 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Apr 2019 |
| BEATBeraprost-314d Added-on to Tyvaso® (BEAT)NCT01908699Beraprost Sodium 314d Modified Release Tablets | Phase 3 | Locked · track to reveal | Completed | 273 est. | 19 Feb 2019 |
| INTREPID - OLInhaled Treprostinil for PAH: Open-label ExtensionNCT01557660inhaled treprostinil | Phase 3 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Dec 2018 |
| H2H-DFUMIRODERM H2H DFU StudyNCT03232333Biologic wound graft | — | Not yet scored | Completed | 53 est. | 20 Sept 2018 |
| Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAHNCT03016468Parenteral Remodulin (treprostinil) injection | Phase 2 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Sept 2018 |
| Miromatrix Biological Mesh for Hiatal Hernia RepairNCT02436681MIROMESH | Na | Locked · track to reveal | Completed | 50 est. | Jul 2018 |
| FREEDOM-EVPhase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral MonotherapyNCT01560624Treprostinil Diolamine | Phase 3 | Locked · track to reveal | Completed | 690 est. | 24 Jun 2018 |
| Complications, Outcomes and Revisions Following Hiatal Hernia Repair With MIROMESHNCT03735862Hepatic derived surgical matrix | — | Not yet scored | Completed | 85 est. | 1 Jun 2018 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial HypertensionNCT02893995Slow Dose Titration Group of Subcutaneous Treprostinil | Phase 4 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Apr 2018 |
| Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary FibrosisNCT02603068Oral treprostinil | Phase 2 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Apr 2018 |
| Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 YearsNCT02276872oral treprostinil | Phase 2 | Locked · track to reveal | Completed | 32 est. | 20 Jul 2017 |
| Safety and Efficacy of APD811 in Pulmonary Arterial HypertensionNCT02279160APD811 | Phase 2 | Locked · track to reveal | Completed | 61 est. | Jun 2017 |
| Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma PatientsNCT02693171Dinutuximab | — | Not yet scored | StoppedTerminated | 13 est. | 19 Dec 2016 |
| MIRODERM™ for Complex Wounds in an Inpatient Setting (MIRODERM CLOSure)NCT02732548Negative Pressure Wound Therapy (NPWT) | Na | Locked · track to reveal | StoppedWithdrawn | 0 est. | Dec 2016 |
| MIROMESH PM-1Miromatrix Biological Mesh for Ventral Hernia RepairNCT02408458MIROMESH® | Na | Locked · track to reveal | StoppedWithdrawn | 0 est. | Apr 2016 |
| A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 InhibitorNCT01458236Beraprost Sodium 314d Modified Release Tablets | Phase 3 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Mar 2016 |